<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k063006.txt
<DESCRIPTION>FORM 8-K
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of Report (Date of Earliest Event Reported): June 30, 2006


                          LIFE SCIENCES RESEARCH, INC.
                         ------------------------------
             (Exact name of registrant as specified in its charter)


 Maryland                          0-33505                       52-2340150
 --------                          -------                       ----------
(State or other jurisdiction     (Commission File Number)     (I.R.S. Employer
  of incorporation)                                          Identification No.)


           P.O. BOX 2360, METTLERS ROAD, EAST MILLSTONE, NJ 08875-2360
                    (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
        REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: 732-649-9961


                                 Not Applicable
                            -------------------------
           Former name or former address, if changed since last report


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[  ] Written communications  pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[  ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[  ] Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement  communications  pursuant  to Rule  13e-4(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Item 1.02.  Termination of a Material Definitive Agreement.

On June 14, 2005, Life Sciences  Research,  Inc. and subsidiaries  (collectively
"LSR"  or  the  "Company")  entered  into  and  consummated  purchase  and  sale
agreements   with  Alconbury   Estates  Inc.  and   subsidiaries   (collectively
"Alconbury")  for the  sale  and  leaseback  of the  Company's  three  operating
facilities  in  Huntingdon  and Eye,  England  and East  Millstone,  New Jersey.
Alconbury  was a newly formed  company  wholly owned by LSR's  Chairman and CEO,
Andrew Baker. The total consideration paid by Alconbury for the three properties
was $40 million,  consisting  of $30 million  cash and a five year,  $10 million
variable  rate  subordinated  promissory  note (the  "Promissory  Note"),  which
Alconbury agreed to make a best effort to repay within twelve months.

On June 30, 2006, the Promissory  Note was paid in full,  including  accrued but
unpaid interest through that date, in an aggregate amount of $10.6 million.

<PAGE>


                                   SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


July 5, 2005                         LIFE SCIENCES RESEARCH, INC.


                                     By:      /s/ Mark L. Bibi
                                     Name:    Mark L. Bibi
                                     Title:   Secretary & General Counsel


</TEXT>
</DOCUMENT>